Merck Announces Phase 3 KEYNOTE-671 Trial with Event-Free Survival (EFS) as the Primary Endpoint in Patients With Resectable Stage II, IIIA, or IIIB Non-Small Cell Lung Cancer – Merck

Merck Announces Phase 3 KEYNOTE-671 Trial with Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA, or IIIB Non-Small Cell Lung CancerMerck
Merck ends latest Keytruda trial in aggressive prostate cancer campaign, takes another hit in lung cancerFiercePharma
Merck Provides Update on KEYNOTE-641 and KEYNOTE-789 Phase 3 Trialsbusiness thread
Standard therapy pembrolizumab plus fails in mCRPC and EGFR mutant NSCLC trialsOncLive
Merck’s Keytruda bounces back from trial double flop with interim victory in prior lung cancerFiercePharma